Scottsdale, Ariz. – September 12, 2026 -- An FDA advisory panel voted 8-6-1 in July 2026 to recommend adding BPC-157 free base and BPC-157 acetate to the Section 503A Bulks List, a move that would let pharmacies compound the peptide more broadly if finalized. The vote does not make BPC-157 FDA-approved, and the recommendation is non-binding.